Scarica l'app Stockscreener
66.73
0.18%
0.12
Dopo l'orario di chiusura:
66.00
-0.73
-1.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$66.61
Aprire:
$66.15
Volume 24 ore:
2.48M
Relative Volume:
1.28
Capitalizzazione di mercato:
$8.22B
Reddito:
$88.04M
Utile/perdita netta:
$-784.96M
Rapporto P/E:
-10.21
EPS:
-6.5335
Flusso di cassa netto:
$-534.82M
1 W Prestazione:
+5.13%
1M Prestazione:
+8.63%
6M Prestazione:
+18.48%
1 anno Prestazione:
+65.79%
Intervallo 1D:
$65.42
$68.71
Intervallo di 1 settimana:
$61.67
$68.71
Portata 52W:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
66.73 | 8.22B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-18 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance UK
Aberdeen Group plc Sells 444,771 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics MYQORZO Approval And CEO Sale Put Valuation In Focus - finance.yahoo.com
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK
CYTK PE Ratio & Valuation, Is CYTK Overvalued - intellectia.ai
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire
Barclays Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $95 - Moomoo
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cytokinetics (CYTK): CEO Blum sells $499k in shares - Investing.com UK
Cytokinetics (CYTK): CEO Blum sells $499k in shares By Investing.com - Investing.com Canada
Insider sale: Cytek (NASDAQ: CYTK) files to sell 45,000 RSUs - Stock Titan
Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares, retains large stake - Stock Titan
CYTK Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Callos, Cytokinetics EVP, sells $236k in shares By Investing.com - Investing.com Australia
Callos, Cytokinetics EVP, sells $236k in shares - Investing.com
3,639 RSUs registered; CYTK (NASDAQ: CYTK) insider 10b5-1 sales listed - Stock Titan
Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004 - Stock Titan
DAFNA Capital Management LLC's Cytokinetics Inc(CYTK) Holding History - GuruFocus
Retail Trends: Is Cytokinetics Incorporated trading at a discount2026 Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating - 富途牛牛
Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - MSN
Cytokinetics Inc (HAM:KK3A) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Aug Drivers: What are the future prospects of Cytokinetics Incorporated2026 Macro Impact & Verified Entry Point Detection - baoquankhu1.vn
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cytokinetics Inc Stock Intrinsic Values | HAM:KK3A - GuruFocus
Cytokinetics Inc (HAM:KK3A) Competitors 2026 - GuruFocus
Should you avoid Cytokinetics Incorporated stock right nowQuarterly Risk Review & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Vanguard disaggregates holdings; CYTK filings now split among subsidiaries (CYTK) - Stock Titan
Cytokinetics Inc (HAM:KK3A) Dividend - gurufocus.com
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report? - Yahoo Finance
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart.com
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics (STU:KK3A) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Aug Catalysts: What is the long term forecast for Cytokinetics Incorporated stockShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-03-22 | Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:CYTK | Press Release - Stockhouse
Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP - MarketBeat
Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock - MarketBeat
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):